1-8 of 8
Peter Ordentlich
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

Daniel Wolff, Corey Cutler, Stephanie J. Lee, Iskra Pusic, Henrique Bittencourt, Jennifer White, Mehdi Hamadani, Sally Arai, Amandeep Salhotra, Jose A. Pérez-Simón, Amin Alousi, Hannah Choe, Mi Kwon, Arancha Bermúdez, Inho Kim, Gerard Socié, Vedran Radojcic, Timothy O'Toole, Chuan Tian, Peter Ordentlich, Zachariah DeFilipp, Carrie L. Kitko
Journal: Blood
Blood (2023) 142 (Supplement 1): 1.
https://doi.org/10.1182/blood-2023-186963
Published: 2023
Journal Articles

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A -Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study

Ghayas C. Issa, Ibrahim Aldoss, John F. DiPersio, Branko Cuglievan, Richard M. Stone, Martha L. Arellano, Michael J. Thirman, Manish R. Patel, David Dickens, Shalini Shenoy, Neerav Shukla, Galit Rosen, Rebecca G. Bagley, Michael L. Meyers, Kate Madigan, Peter Ordentlich, Yu Gu, Steven Smith, Gerard M. McGeehan, Eytan Stein
Journal: Blood
Blood (2022) 140 (Supplement 1): 150–152.
https://doi.org/10.1182/blood-2022-164849
Published: 2022
Journal Articles

Inhibition of Menin, BCL-2, and FLT3 Combined with a Hypomethylating Agent Cures NPM1/FLT3 -ITD/-TKD Mutant AML in a PDX Model

Bing Z Carter, Po Yee Mak, Wenjing Tao, Lauren B Ostermann, Duncan Mak, Boazhen Ke, Peter Ordentlich, Gerard M. McGeehan, Michael Andreeff
Journal: Blood
Blood (2022) 140 (Supplement 1): 3063–3064.
https://doi.org/10.1182/blood-2022-158570
Published: 2022
Journal Articles

Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

Stephanie J. Lee, Mukta Arora, Zachariah Defilipp, Mohammad Issam Abu Zaid, Antonio Di Stasi, Vedran Radojcic, Michael L. Meyers, Hope Qamoos, Peter Ordentlich, Christine Quaranto, Aaron Schmitt, Yu Gu, Amandeep Salhotra, Iskra Pusic, Carrie Lynn Kitko
Journal: Blood
Blood (2021) 138 (Supplement 1): 263.
https://doi.org/10.1182/blood-2021-146050
Published: 2021
Journal Articles

Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML

Bing Z. Carter, Wenjing Tao, Po Yee Mak, Lauren B. Ostermann, Duncan Mak, Gerard McGeehan, Peter Ordentlich, Michael Andreeff
Journal: Blood
Blood (2021) 138 (17): 1637–1641.
https://doi.org/10.1182/blood.2021011917
Published: 2021
Includes: Supplemental data
Journal Articles

Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

Mukta Arora, MD, Madan Jagasia, MBBS, MS, MMHC, Antonio Di Stasi, MD, Michael L Meyers, MD PhD, Christine Quaranto, Aaron Schmitt, Serap Sankoh, Mohammad Issam Abu Zaid, MBBS, Geoff R Hill, MD, Daniel J. Weisdorf, MD, Bruce R. Blazar, MD, Peter Ordentlich, PhD, Stephanie J. Lee, MDMPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-141553
Published: 2020
Journal Articles

A Phase I Study Of The Histone Deacetylase Inhibitor Entinostat Plus Clofarabine For Philadelphia Chromosome Negative, Poor Risk (Newly Diagnosed Older Adults or Adults with Relapsed and Refractory Disease) Acute Lymphoblastic Leukemia Or Bilineage/Biphenotypic Leukemia

Hetty E Carraway, MD, MBA, Judith E. Karp, MD, Ivana Gojo, MD, Keith W. Pratz, MD, Nilanjan Ghosh, MD, PhD, Steven D. Gore, MD, Margaret M. Showel, MD, Mark Levis, MD, PhD, B. Douglas Smith, Jacqueline Greer, James G. Herman, MD, Lia Gore, MD, Min-Jung Lee, PhD, Sunmin Lee, PhD, Peter Ordentlich, PhD, Richard Piekarz, MD, PhD, Jane Trepel, PhD
Journal: Blood
Blood (2013) 122 (21): 1427.
https://doi.org/10.1182/blood.V122.21.1427.1427
Published: 2013
Journal Articles

Alkylator-Induced DNA Damage Response in Multiple Myeloma (MM) Cells Is Amplified by Histone Deacetylase (HDAC) Inhibition, Resulting in Significant Synergism in Cell Death

Choon Kee Lee, MD, Shuiliang Wang, M.D., Xiaoping Huang, M.D., John Ryder, M.D., Peter Ordentlich, PhD, Bolin Liu, M.D.
Journal: Blood
Blood (2008) 112 (11): 5157.
https://doi.org/10.1182/blood.V112.11.5157.5157
Published: 2008